Patents by Inventor Sabine Ehrt

Sabine Ehrt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONDITIONALLY REPLICATING M. BOVIS BCG
    Publication number: 20230039352
    Abstract: Conditionally replicating recombinant cells, compositions and vaccines having the cells, and methods of using the cells, are provided.
    Type: Application
    Filed: January 8, 2021
    Publication date: February 9, 2023
    Inventors: Dirk Schnappinger, Sabine Ehrt
  • membrane protease as a target for inhibitors of intrabacterial pH homeostasis
    Patent number: 8951992
    Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: February 10, 2015
    Assignee: Cornell University
    Inventors: Carl Nathan, Sabine Ehrt, Omar Vandal, Crystal Darby
  • MYCOBACTERIUM MEMBRANE PROTEASE AS A TARGET FOR INHIBITORS OF INTRABACTERIAL pH HOMEOSTASIS
    Publication number: 20110190234
    Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.
    Type: Application
    Filed: July 20, 2009
    Publication date: August 4, 2011
    Applicant: CORNELL UNIVERSITY
    Inventors: Carl Nathan, Sabine Ehrt, Omar Vandal, Crystal Darby
  • DNA molecule conferring on Mycobacterium tuberculosis resistance against antimicrobial reactive oxygen and nitrogen intermediates
    Patent number: 6177086
    Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis resistance to antimicrobial reactive oxygen intermediates and reactive nitrogen intermediates. The protein encoded by this DNA molecule is useful in vaccines to prevent invention by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein or polypeptide is also useful as a therapeutic in treating conditions mediated by the production of reactive oxygen intermediates and nitrogen intermediates.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: January 23, 2001
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Lee W. Riley, Carl F. Nathan, Sabine Ehrt